Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press39810.17650/1994-4098-2014-0-3-70-77GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАLow molecular weight blood plasma proteome – a source of differential diagnostic biomarkers of ovarian cancerНизкомолекулярный протеом плазмы крови – источник биомаркеров для дифференциальной диагностики рака яичниковShevchenkoV. Ye.ШевченкоВ. Е.
Russian Federation
vshev@nm.ruArnotskayaN. Ye.АрноцкаяН. Е.
Russian Federation
PogosyanN. R.ПогосянН. Р.
Russian Federation
IoselianyO. G.ИоселианиО. Г.
Russian Federation
GritsayA. N.ГрицайА. Н.
Russian Federation
N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, МоскваN. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow N. I. Pirogov Russian National Research Medical University, Ministry оf Health оf Russia, MoscowФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России, Москва07112014370770711201407112014https://ojrs.abvpress.ru/ojrs/article/view/398

At present, there is no screening test for the early detecting of ovarian cancer, one of the most lethal form of gynaecological malignancy in the worldwide. In this study the new methodology for the search of tumor markers of ovarian cancer, involving profiling the low-molecular blood plasma proteomes, is developed, unified and approved. The given approach included three basic components: pre-preparation of samples, matrix-assisted laser desorption / ionization time-of-flight mass spectrometry and bioinformatics software for mass spectral data processing. Opportunities and prospects of the developed approach for the detection of potential ovarian cancer markers were shown. For search of potential tumor markers, screening of 56 blood plasma samples from ovarian cancer patients and 36 benign ovarian neoplasia samples were carried out.As a result of the present research, peptides / polypeptides which can be used in future for detecting this pathology were found out.

В настоящее время отсутствует скрининговый тест для ранней диагностики рака яичников (РЯ). В этом исследовании разработана, унифицирована и апробирована новая методология поиска биомаркеров РЯ, основанная на профилировании низкомолекулярного протеома (НМП) плазмы крови. Данный подход включает в себя 3 основных компонента: предварительную подготовку образцов, времяпролетную масс-спектрометрию с матрично-активированной лазерной десорбцией / ионизацией, обработку данных с помощью биоинформационного пакета программ. Продемонстрированы возможности и перспективность разработанного подхода для обнаружения потенциальных маркеров РЯ. Проведен скрининг образцов плазмы крови 56 больных РЯ, 36 больных доброкачественными опухолями яичников. В результате проведенного исследования обнаружены пептиды / полипептиды, которые могут в перспективе использоваться для дифференциальной диагностики РЯ.

biomarkersovarian cancerbenign ovarian neoplasiaproteomeblood plasmamass spectrometryбиомаркерырак яичниковдоброкачественные опухоли яичниковпротеомплазма кровимасс-спектрометрия1. Jacobs I., Oram D., Fairbanks J. et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990;97(10):922–9.Jacobs I., Oram D., Fairbanks J. et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990;97(10):922–9.2. Bast R.C. Jr., Brewer M., Zou C. et al. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res 2007;174:91–100.Bast R.C. Jr., Brewer M., Zou C. et al. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res 2007;174:91–100.3. Woolas R.P., Conaway M.R., Xu F. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111–6.Woolas R.P., Conaway M.R., Xu F. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111–6.4. Moore R.G., McMeekin D.S., Brown A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. GynecolOncol 2009;112(1):40–6.Moore R.G., McMeekin D.S., Brown A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. GynecolOncol 2009;112(1):40–6.5. Шевченко В.Е. Современные масс-спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103–26.Шевченко В.Е. Современные масс-спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103–26.6. Etzioni R., Urban N., Ramsey S. et al. The case for early detection. Nat Rev Cancer 2003;3(4):243–52.Etzioni R., Urban N., Ramsey S. et al. The case for early detection. Nat Rev Cancer 2003;3(4):243–52.7. Aldred S., Grant M.M., Griffiths H.R. The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004;37(11):943–52.Aldred S., Grant M.M., Griffiths H.R. The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004;37(11):943–52.8. Banks R.E., Dunn M.J., Hochstrasser D.F. et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000; 356(9243):1749–56.Banks R.E., Dunn M.J., Hochstrasser D.F. et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000; 356(9243):1749–56.9. Diamandis E.P. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):170.Diamandis E.P. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):170.10. Guillaume E., Zimmermann C., Burkhard P.R. et al. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003;3(8):1495–99.Guillaume E., Zimmermann C., Burkhard P.R. et al. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003;3(8):1495–99.11. Howard B.A., Wang M.Z., Campa M.J. et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ ionization-time of flight spectra analysis. Proteomics 2003;3(9):1720–4.Howard B.A., Wang M.Z., Campa M.J. et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ ionization-time of flight spectra analysis. Proteomics 2003;3(9):1720–4.12. Koopmann J., Zhang Z., White N. et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10(3):860–8.Koopmann J., Zhang Z., White N. et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10(3):860–8.13. Menon U., Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16(4):469–82.Menon U., Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16(4):469–82.14. Petricoin E.F., Ardekani A.M., Hitt B.A. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–7.Petricoin E.F., Ardekani A.M., Hitt B.A. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–7.15. Zheng P.P., Luider T.M., Pieters R. et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62(8):855–62.Zheng P.P., Luider T.M., Pieters R. et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62(8):855–62.16. Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектрометрия 2007;4(4):245–54.Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектрометрия 2007;4(4):245–54.17. Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom (Chichester, Eng) 2010;16(4):539–49.Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom (Chichester, Eng) 2010;16(4):539–49.18. Пятницкий М.А., Лисица А.В., Шевченко В.Е. и др. Выявление дифференциальных признаков плоскоклеточного рака легкого с помощью масс-спектрометрического профилирования плазмы крови. Масс-спектрометрия 2011;8(2):99–105.Пятницкий М.А., Лисица А.В., Шевченко В.Е. и др. Выявление дифференциальных признаков плоскоклеточного рака легкого с помощью масс-спектрометрического профилирования плазмы крови. Масс-спектрометрия 2011;8(2):99–105.19. Villanueva J., Shaffer D.R., Philip J. Differential exoprotease activities confer tumour-specific serum peptidome patterns. J Clin Invest 2006;116(1):271–84.Villanueva J., Shaffer D.R., Philip J. Differential exoprotease activities confer tumour-specific serum peptidome patterns. J Clin Invest 2006;116(1):271–84.20. Ketterlinus R., Hsieh S.Y., Teng S.H. et al. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;Suppl:37–40.Ketterlinus R., Hsieh S.Y., Teng S.H. et al. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;Suppl:37–40.21. Сорокина А.В., Радзинский В.Е., Мустафина Е.А. и др. Масс-спектрометрия – новый подход в диагностике аденомиоза и рака тела матки. Опухоли женской репродуктивной системы 2011;(2):65–72.Сорокина А.В., Радзинский В.Е., Мустафина Е.А. и др. Масс-спектрометрия – новый подход в диагностике аденомиоза и рака тела матки. Опухоли женской репродуктивной системы 2011;(2):65–72.22. Шевченко В.Е., Мадина Х., Поддубная И.В. и др. Вестн РОНЦ им. Н.Н. Блохина РАМН 2011;22(3):27–33.Шевченко В.Е., Мадина Х., Поддубная И.В. и др. Вестн РОНЦ им. Н.Н. Блохина РАМН 2011;22(3):27–33.23. Zhou M., Lucas D.A., Chan K.C. et al. An investigation into the human serum “interactome”. Electrophoresis 2004; 25(9):1289–98.Zhou M., Lucas D.A., Chan K.C. et al. An investigation into the human serum “interactome”. Electrophoresis 2004; 25(9):1289–98.24. Kozak K.R., Amneus M.W., Pusey S.M. et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100(21):12343–8.Kozak K.R., Amneus M.W., Pusey S.M. et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100(21):12343–8.25. Callesen A.K., Mogensen O., Jensen A.K. et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. J Proteomics 2012;75(10):2758–72.Callesen A.K., Mogensen O., Jensen A.K. et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. J Proteomics 2012;75(10):2758–72.26. Fiedler G.M., Baumann S., Leichtle A. et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007;53(3):421–8.Fiedler G.M., Baumann S., Leichtle A. et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007;53(3):421–8.27. Schaub N.P., Jones K.J., Nyalwidhe J.O. et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 2009;208(5):970–7.Schaub N.P., Jones K.J., Nyalwidhe J.O. et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 2009;208(5):970–7.28. Schwamborn K., Krieg R.C., Grosse J. et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009;56(6): 989–99.Schwamborn K., Krieg R.C., Grosse J. et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009;56(6): 989–99.